151 related articles for article (PubMed ID: 32786957)
21. Development of a Screening System for Targeting Carriers Using Peptide-Modified Liposomes and Tissue Sections.
Negishi Y; Hamano N; Sato H; Katagiri F; Takatori K; Endo-Takahashi Y; Kikkawa Y; Nomizu M
Biol Pharm Bull; 2018; 41(7):1107-1111. PubMed ID: 29962407
[TBL] [Abstract][Full Text] [Related]
22. The Effect of Size, Dose, and Administration Route on Zein Nanoparticle Immunogenicity in BALB/c Mice.
Li F; Chen Y; Liu S; Pan X; Liu Y; Zhao H; Yin X; Yu C; Kong W; Zhang Y
Int J Nanomedicine; 2019; 14():9917-9928. PubMed ID: 31908449
[TBL] [Abstract][Full Text] [Related]
23. Failure of active targeting by a cholesterol-anchored ligand and improvement by altering the lipid composition to prevent ligand desorption.
Yamamoto S; Sakurai Y; Harashima H
Int J Pharm; 2018 Jan; 536(1):42-49. PubMed ID: 29126905
[TBL] [Abstract][Full Text] [Related]
24. Dual-functional c(RGDyK)-decorated Pluronic micelles designed for antiangiogenesis and the treatment of drug-resistant tumor.
Chen Y; Zhang W; Huang Y; Gao F; Fang X
Int J Nanomedicine; 2015; 10():4863-81. PubMed ID: 26257522
[TBL] [Abstract][Full Text] [Related]
25. Cyclic RGD peptide-modified liposomal drug delivery system for targeted oral apatinib administration: enhanced cellular uptake and improved therapeutic effects.
Song Z; Lin Y; Zhang X; Feng C; Lu Y; Gao Y; Dong C
Int J Nanomedicine; 2017; 12():1941-1958. PubMed ID: 28331317
[TBL] [Abstract][Full Text] [Related]
26. Ligand-Modified Erythrocyte Membrane-Cloaked Metal-Organic Framework Nanoparticles for Targeted Antitumor Therapy.
Lin Y; Zhong Y; Chen Y; Li L; Chen G; Zhang J; Li P; Zhou C; Sun Y; Ma Y; Xie Z; Liao Q
Mol Pharm; 2020 Sep; 17(9):3328-3341. PubMed ID: 32804508
[TBL] [Abstract][Full Text] [Related]
27. Delivery of RGD-modified liposome as a targeted colorectal carcinoma therapy and its autophagy mechanism.
Ren Y; Yuan B; Hou S; Sui Y; Yang T; Lv M; Zhou Y; Yu H; Li S; Peng H; Chang N; Liu Y
J Drug Target; 2021 Sep; 29(8):863-874. PubMed ID: 33507113
[TBL] [Abstract][Full Text] [Related]
28. Efficient siRNA Delivery by Lipid Nanoparticles Modified with a Nonstandard Macrocyclic Peptide for EpCAM-Targeting.
Sakurai Y; Mizumura W; Murata M; Hada T; Yamamoto S; Ito K; Iwasaki K; Katoh T; Goto Y; Takagi A; Kohara M; Suga H; Harashima H
Mol Pharm; 2017 Oct; 14(10):3290-3298. PubMed ID: 28789523
[TBL] [Abstract][Full Text] [Related]
29. In Vitro and In Vivo Efficacy of Self-Assembling RGD Peptide Amphiphiles for Targeted Delivery of Paclitaxel.
Saraf P; Li X; Wrischnik L; Jasti B
Pharm Res; 2015 Sep; 32(9):3087-101. PubMed ID: 26063045
[TBL] [Abstract][Full Text] [Related]
30. Sequential treatment of drug-resistant tumors with RGD-modified liposomes containing siRNA or doxorubicin.
Jiang J; Yang SJ; Wang JC; Yang LJ; Xu ZZ; Yang T; Liu XY; Zhang Q
Eur J Pharm Biopharm; 2010 Oct; 76(2):170-8. PubMed ID: 20600887
[TBL] [Abstract][Full Text] [Related]
31. In vitro and in vivo platelet targeting by cyclic RGD-modified liposomes.
Srinivasan R; Marchant RE; Gupta AS
J Biomed Mater Res A; 2010 Jun; 93(3):1004-15. PubMed ID: 19743511
[TBL] [Abstract][Full Text] [Related]
32. Targeted thrombolysis by using c-RGD-modified N,N,N-Trimethyl Chitosan nanoparticles loaded with lumbrokinase.
Liao J; Ren X; Yang B; Li H; Zhang Y; Yin Z
Drug Dev Ind Pharm; 2019 Jan; 45(1):88-95. PubMed ID: 30198790
[TBL] [Abstract][Full Text] [Related]
33. An efficient PEGylated liposomal nanocarrier containing cell-penetrating peptide and pH-sensitive hydrazone bond for enhancing tumor-targeted drug delivery.
Ding Y; Sun D; Wang GL; Yang HG; Xu HF; Chen JH; Xie Y; Wang ZQ
Int J Nanomedicine; 2015; 10():6199-214. PubMed ID: 26491292
[TBL] [Abstract][Full Text] [Related]
34. Pharmaceutical development and regulatory considerations for nanoparticles and nanoparticulate drug delivery systems.
Narang AS; Chang RK; Hussain MA
J Pharm Sci; 2013 Nov; 102(11):3867-82. PubMed ID: 24037829
[TBL] [Abstract][Full Text] [Related]
35. Cyclic RGDyK conjugation facilitates intracellular drug delivery of polymeric micelles to integrin-overexpressing tumor cells and neovasculature.
Yin J; Li Z; Yang T; Wang J; Zhang X; Zhang Q
J Drug Target; 2011 Jan; 19(1):25-36. PubMed ID: 20233083
[TBL] [Abstract][Full Text] [Related]
36. Efficient delivery of docetaxel for the treatment of brain tumors by cyclic RGD-tagged polymeric micelles.
Li AJ; Zheng YH; Liu GD; Liu WS; Cao PC; Bu ZF
Mol Med Rep; 2015 Apr; 11(4):3078-86. PubMed ID: 25434368
[TBL] [Abstract][Full Text] [Related]
37. Enhanced anticancer efficacy of paclitaxel through multistage tumor-targeting liposomes modified with RGD and KLA peptides.
Sun J; Jiang L; Lin Y; Gerhard EM; Jiang X; Li L; Yang J; Gu Z
Int J Nanomedicine; 2017; 12():1517-1537. PubMed ID: 28280323
[TBL] [Abstract][Full Text] [Related]
38. Improvement of chemosensitivity and inhibition of migration via targeting tumor epithelial-to-mesenchymal transition cells by ADH-1-modified liposomes.
Guo Z; Li W; Yuan Y; Zheng K; Tang Y; Ma K; Cui C; Wang L; He B; Zhang Q
Drug Deliv; 2018 Nov; 25(1):112-121. PubMed ID: 29260912
[TBL] [Abstract][Full Text] [Related]
39. An optimized two-vial formulation lipid nanoemulsion of paclitaxel for targeted delivery to tumor.
Chen L; Chen B; Deng L; Gao B; Zhang Y; Wu C; Yu N; Zhou Q; Yao J; Chen J
Int J Pharm; 2017 Dec; 534(1-2):308-315. PubMed ID: 28986321
[TBL] [Abstract][Full Text] [Related]
40. Amplification of antibody responses to antigen using small multilamellar vesicles for delivery system.
Gaubert S; Delord B; Roux D; Amédée J; Bayer E; Auriault C; Laversanne R
Drug Deliv; 2005; 12(2):69-74. PubMed ID: 15824031
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
